Akeega combines niraparib, a PARP inhibitor, and abiraterone acetate, a CYP17 inhibitor, into a single tablet for BRCA2-mutated mCSPC.

Prostate cancer is one of the most common cancers in men but often goes unnoticed. Experts stress early screening, awareness ...

The old belief that testosterone therapy increases prostate cancer or makes it worse is no longer backed up by modern ...

Staging means finding out how far prostate cancer has spread in your body. Physicians group prostate cancers into stages I (1) through IV (4), with stage I being the least advanced and stage IV being ...

A University of Kentucky Markey Cancer Center study reveals how prostate cancer cells adapt their metabolism to thrive in bone tissue, offering a potential new treatment target for patients with ...

Researchers identify APOC1 and NOP16 as promising prostate cancer biomarkers that could aid early diagnosis. Learn more about ...

There is a shadow disease that often lurks unnoticed, growing quietly within a man’s body which is hidden behind the mundane routine of daily life, masked by ag ...

The Phase 3 AMPLITUDE trial led by UCL found that adding the PARP inhibitor niraparib to standard hormone therapy may slow ...

Terminally ill cycling star Sir Chris Hoy has revealed that there was one key sign of cancer he brushed off as 'just getting ...

Nigeria records over 18,000 new prostate cancer cases annually, accounting for the highest cancer burden among men in the country.